Ideaya Biosciences Inc

+0.75 (+4.12%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)577.20M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.07 Million
Adjusted EPS-$0.33
See more estimates
10-Day MA$18.75
50-Day MA$16.71
200-Day MA$13.45
See more pivots

IDEAYA Biosciences, Inc. Stock, NASDAQ:IDYA

7000 Shoreline Court, Suite 350, South San Francisco, California 94080
United States of America
Phone: +1.650.443.6209
Number of Employees: 47


IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.